Search
EHA-LSHBT Virtual Hematology Updates
EHA and the Lebanese Society of Hematology and Blood Transfusion (LSHBT) have initiated a webinar course dedicated to practitioners who manage patients with benign and hematologic malignancies.
Read moreCommonalities and Differences in Myeloid Malignancies: Insights from the EHA-SWG Scientific Meeting on MDS, MPN, and AML
November 2-4 - Budapest, Hungary
Meeting Chairs:
Konstanze Döhner, University Hospital Ulm, Germany
Claire Harrison, Guy's and St.
FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement
We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).
Read moreResearch trainings
Old ways won't open new doors. Via non-pecuniary awards, EHA strives to accelerate the careers of promising post-docs in translational or clinical research.
Read moreEHA-ECL led statement calls for protection of the Hospital Exemption
The hospital exemption (HE) is a vital provision within the EU's pharmaceutical legislation, currently subject to a revision.
Read moreEHA policy on double awarding
EHA is guided by the concept of supporting as many young investigators/clinicians as possible in their career development. Therefore, double awarding is not allowed. Winning an award excludes the award winner from winning another award while receiving the first.
Read moreEHA-Balkan Hematology Day 2023
EHA is joining forces with the national societies from the Balkan countries and co-organizing with them the 4th edition of the EHA-Balkan Hematology Day.
Read more5th European CAR T-cell Meeting
The European Hematology Association (EHA) and the EBMT are excited to announce the 5th edition of the jointly organized European CAR T-cell Meeting.
Read more